Intrexon, which is developing synthetic biology technologies, announced terms for its IPO on Monday. The Germantown, MD-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Intrexon would command a fully diluted market value of $1.4 billion.
Intrexon, which was founded in 1998 and booked $16 million in sales for the 12 months ended March 31, 2013, plans to list on the NYSE under the symbol XON. Intrexon initially filed confidentially on May 10, 2013. J.P. Morgan and Barclays are the joint bookrunners on the deal.
